Table S1. Normality test results for age and BMI (n = 1130)

Variable	n	Mean_SD	Median_IQR	Shapiro_Wilk_P	KS_test_P
BMI	1130	23.09 ± 3.26	22.89 (20.89-25.16)	0.0000153	0.152
Age	1130	58.95 ± 13.95	58 (49-69)	0.00000259	0.0159

Normality was assessed using the Shapiro-Wilk test and the Kolmogorov-Smirnov test. Given the large sample size (n = 1130), the Shapiro-Wilk test is sensitive to minor departures from normality. Descriptive statistics showed mean and median values were similar for both variables, indicating approximate symmetry. Accordingly, nonparametric methods (Wilcoxon rank-sum test) were used for group comparisons of continuous variables.

Table S2. BRAF V600E-positive versus BRAF V600E-negative across tumor differentiation grades

Tumor differentiation	G1+G2 differentiated CRC			G3 differentiated CRC		
	BRAF V600E (-)	BRAF V600E (+)	P-value	BRAF V600E (-)	BRAF V600E (+)	P-value
N	821	72		204	33	
BMI			0.024			0.473
Median (IQR)	23 (21.1-25.2)	21.8 (20.1-24.3)		22.6 (20.7-25.1)	22 (20.2-24.4)	
Age			0.337			0.281
Median (IQR)	58 (50-69)	57 (48.8-67.2)		57 (46-70)	61 (47-73)	
Sex			0.407			0.535
Male	492 (59.9%)	39 (54.2%)		102 (50%)	19 (57.6%)	
Female	329 (40.1%)	33 (45.8%)		102 (50%)	14 (42.4%)	
Inflammatory status			0.358			0.421
No	756 (92.1%)	69 (95.8%)		193 (94.6%)	30 (90.9%)	
Yes	65 (7.9%)	3 (4.2%)		11 (5.4%)	3 (9.1%)	
Vascular invasion			0.608			0.243
No	719 (87.6%)	61 (84.7%)		164 (80.4%)	23 (69.7%)	
Yes	102 (12.4%)	11 (15.3%)		40 (19.6%)	10 (30.3%)	
Perineural invasion			0.045			1
No	547 (66.6%)	39 (54.2%)		123 (60.3%)	20 (60.6%)	
Yes	274 (33.4%)	33 (45.8%)		81 (39.7%)	13 (39.4%)	
T Stage			0.312			0.746
T1	65 (7.9%)	6 (8.3%)		1 (0.5%)	0 (0%)	
T2	170 (20.7%)	12 (16.7%)		19 (9.3%)	3 (9.1%)	
T3	496 (60.4%)	41 (56.9%)		127 (62.3%)	23 (69.7%)	
T4	90 (11%)	13 (18.1%)		57 (27.9%)	7 (21.2%)	
N Stage			0.732			0.222
N0	528 (64.3%)	48 (66.7%)		98 (48%)	11 (33.3%)	
N1	226 (27.5%)	17 (23.6%)		66 (32.4%)	12 (36.4%)	
N2	67 (8.2%)	7 (9.7%)		40 (19.6%)	10 (30.3%)	
M stage			0.491			1
M0	814 (99.1%)	71 (98.6%)		203 (99.5%)	33 (100%)	
M1	7 (0.9%)	1 (1.4%)		1 (0.5%)	0 (0%)	
TNM Stage			0.503			0.254
I	200 (24.4%)	14 (19.4%)		15 (7.4%)	0 (0%)	
II	324 (39.5%)	33 (45.8%)		83 (40.7%)	11 (33.3%)	
III	290 (35.3%)	24 (33.3%)		105 (51.5%)	22 (66.7%)	
IV	7 (0.9%)	1 (1.4%)		1 (0.5%)	0 (0%)	
Tumor location			0.891			0.029
Colon	386 (47%)	35 (48.6%)		123 (60.3%)	27 (81.8%)	
Rectum	435 (53%)	37 (51.4%)		81 (39.7%)	6 (18.2%)	
Mismatch repair status			0.121			0.142
pMMR	788 (96%)	66 (91.7%)		173 (84.8%)	24 (72.7%)	
dMMR	33 (4%)	6 (8.3%)		31 (15.2%)	9 (27.3%)	
MLH1			0.434			0.57
-	21 (2.6%)	3 (4.2%)		24 (11.8%)	5 (15.2%)	
+	800 (97.4%)	69 (95.8%)		180 (88.2%)	28 (84.8%)	
MSH2			0.131			0.308
-	6 (0.7%)	2 (2.8%)		6 (2.9%)	2 (6.1%)	
+	815 (99.3%)	70 (97.2%)		198 (97.1%)	31 (93.9%)	
MSH6			0.103			1
-	5 (0.6%)	2 (2.8%)		3 (1.5%)	0 (0%)	
+	816 (99.4%)	70 (97.2%)		201 (98.5%)	33 (100%)	
PMS2			0.473			0.186
-	24 (2.9%)	3 (4.2%)		26 (12.7%)	7 (21.2%)	
+	797 (97.1%)	69 (95.8%)		178 (87.3%)	26 (78.8%)	
Ki67			0.319			0.566
Unknown	145 (17.7%)	8 (11.1%)		51 (25%)	12 (36.4%)	
Low (<20%)	13 (1.6%)	0 (0%)		2 (1%)	0 (0%)	
Intermediate (20-40%)	40 (4.9%)	2 (2.8%)		10 (4.9%)	1 (3%)	
High (>40%)	623 (75.9%)	62 (86.1%)		141 (69.1%)	20 (60.6%)	
HER2			0.381			0.716
Unknown	257 (31.3%)	26 (36.1%)		58 (28.4%)	12 (36.4%)	
Negative (-/1+)	511 (62.2%)	41 (56.9%)		128 (62.7%)	20 (60.6%)	
Equivocal (2+)	50 (6.1%)	4 (5.6%)		15 (7.4%)	1 (3%)	
Positive (3+)	3 (0.4%)	1 (1.4%)		3 (1.5%)	0 (0%)	
CDX2			0.233			0.299
Unknown	133 (16.2%)	7 (9.7%)		30 (14.7%)	3 (9.1%)	
Negative	13 (1.6%)	0 (0%)		2 (1%)	1 (3%)	
Positive	675 (82.2%)	65 (90.3%)		172 (84.3%)	29 (87.9%)	
CK20			0.339			0.407
Unknown	158 (19.2%)	9 (12.5%)		37 (18.1%)	5 (15.2%)	
Negative	18 (2.2%)	1 (1.4%)		8 (3.9%)	3 (9.1%)	
Positive	645 (78.6%)	62 (86.1%)		159 (77.9%)	25 (75.8%)	

Continuous variables were compared using the Wilcoxon rank-sum test; categorical variables were compared using Pearson's chi-squared test (with continuity correction for 2 × 2 tables) or Fisher's exact test when expected cell counts were small or when contingency tables contained sparse cells. All tests were two-sided. A P value < 0.05 was considered statistically significant.

Abbreviations: BMI, body mass index; IQR, interquartile range; dMMR, deficient mismatch repair; pMMR, proficient mismatch repair; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated.

Table S3. BRAF V600E-positive versus BRAF V600E-negative across Age of onset

Age	Late-onset colorectal cancer			Early-onset colorectal cancer		
	BRAF V600E (-)	BRAF V600E (+)	P-value	BRAF V600E (-)	BRAF V600E (+)	P-value
N	757	76		268	29	
BMI			0.005			0.828
Median (IQR)	23.2 (21.3-25.5)	21.8 (20-24.1)		22.2 (20.2-24.6)	22.1 (20.4-24.9)	
Sex			0.87			0.768
Male	461 (60.9%)	45 (59.2%)		133 (49.6%)	13 (44.8%)	
Female	296 (39.1%)	31 (40.8%)		135 (50.4%)	16 (55.2%)	
Tumor differentiation			0.021			0.304
G1+G2	617 (81.5%)	53 (69.7%)		204 (76.1%)	19 (65.5%)	
G3	140 (18.5%)	23 (30.3%)		64 (23.9%)	10 (34.5%)	
Inflammatory status			0.809			0.332
No	709 (93.7%)	71 (93.4%)		240 (89.6%)	28 (96.6%)	
Yes	48 (6.3%)	5 (6.6%)		28 (10.4%)	1 (3.4%)	
Vascular invasion			0.627			0.078
No	658 (86.9%)	64 (84.2%)		225 (84%)	20 (69%)	
Yes	99 (13.1%)	12 (15.8%)		43 (16%)	9 (31%)	
Perineural invasion			0.0422			1
No	502 (66.3%)	41 (53.9%)		168 (62.7%)	18 (62.1%)	
Yes	255 (33.7%)	35 (46.1%)		100 (37.3%)	11 (37.9%)	
T Stage			0.607			0.077
T1	46 (6.1%)	6 (7.9%)		20 (7.5%)	0 (0%)	
T2	153 (20.2%)	11 (14.5%)		36 (13.4%)	4 (13.8%)	
T3	455 (60.1%)	49 (64.5%)		168 (62.7%)	15 (51.7%)	
T4	103 (13.6%)	10 (13.2%)		44 (16.4%)	10 (34.5%)	
N Stage			0.233			0.518
N0	475 (62.7%)	42 (55.3%)		151 (56.3%)	17 (58.6%)	
N1	214 (28.3%)	23 (30.3%)		78 (29.1%)	6 (20.7%)	
N2	68 (9%)	11 (14.5%)		39 (14.6%)	6 (20.7%)	
M stage			1			0.266
M0	751 (99.2%)	76 (100%)		266 (99.3%)	28 (96.6%)	
M1	6 (0.8%)	0 (0%)		2 (0.7%)	1 (3.4%)	
TNM Stage			0.445			0.174
I	168 (22.2%)	12 (15.8%)		47 (17.5%)	2 (6.9%)	
II	303 (40%)	30 (39.5%)		104 (38.8%)	14 (48.3%)	
III	280 (37%)	34 (44.7%)		115 (42.9%)	12 (41.4%)	
IV	6 (0.8%)	0 (0%)		2 (0.7%)	1 (3.4%)	
Tumor location			0.793			0.007
Colon	381 (50.3%)	40 (52.6%)		128 (47.8%)	22 (75.9%)	
Rectum	376 (49.7%)	36 (47.4%)		140 (52.2%)	7 (24.1%)	
Mismatch repair status			<0.001			1
pMMR	721 (95.2%)	64 (84.2%)		240 (89.6%)	26 (89.7%)	
dMMR	36 (4.8%)	12 (15.8%)		28 (10.4%)	3 (10.3%)	
MLH1			0.01			0.234
-	27 (3.6%)	8 (10.5%)		18 (6.7%)	0 (0%)	
+	730 (96.4%)	68 (89.5%)		250 (93.3%)	29 (100%)	
MSH2			0.029			0.565
-	5 (0.7%)	3 (3.9%)		7 (2.6%)	1 (3.4%)	
+	752 (99.3%)	73 (96.1%)		261 (97.4%)	28 (96.6%)	
MSH6			0.097			1
-	4 (0.5%)	2 (2.6%)		4 (1.5%)	0 (0%)	
+	753 (99.5%)	74 (97.4%)		264 (98.5%)	29 (100%)	
PMS2			0.017			1
-	30 (4%)	8 (10.5%)		20 (7.5%)	2 (6.9%)	
+	727 (96%)	68 (89.5%)		248 (92.5%)	27 (93.1%)	
Ki67			0.808			0.957
Unknown	141 (18.6%)	15 (19.7%)		55 (20.5%)	5 (17.2%)	
Low (<20%)	11 (1.5%)	0 (0%)		4 (1.5%)	0 (0%)	
Intermediate (20-40%)	35 (4.6%)	2 (2.6%)		15 (5.6%)	1 (3.4%)	
High (>40%)	570 (75.3%)	59 (77.6%)		194 (72.4%)	23 (79.3%)	
HER2			0.288			0.449
Unknown	238 (31.4%)	32 (42.1%)		77 (28.7%)	6 (20.7%)	
Negative (-/1+)	468 (61.8%)	41 (53.9%)		171 (63.8%)	20 (69%)	
Equivocal (2+)	48 (6.3%)	3 (3.9%)		17 (6.3%)	2 (6.9%)	
Positive (3+)	3 (0.4%)	0 (0%)		3 (1.1%)	1 (3.4%)	
CDX2			0.558			0.257
Unknown	126 (16.6%)	9 (11.8%)		37 (13.8%)	1 (3.4%)	
Negative	11 (1.5%)	1 (1.3%)		4 (1.5%)	0 (0%)	
Positive	620 (81.9%)	66 (86.8%)		227 (84.7%)	28 (96.6%)	
CK20			0.208			0.0617
Unknown	147 (19.4%)	13 (17.1%)		48 (17.9%)	1 (3.4%)	
Negative	16 (2.1%)	4 (5.3%)		10 (3.7%)	0 (0%)	
Positive	594 (78.5%)	59 (77.6%)		210 (78.4%)	28 (96.6%)	

Continuous variables were compared using the Wilcoxon rank-sum test; categorical variables were compared using Pearson's chi-squared test (with continuity correction for 2 × 2 tables) or Fisher's exact test when expected cell counts were small or when contingency tables contained sparse cells. All tests were two-sided. A P value < 0.05 was considered statistically significant.

Abbreviations: BMI, body mass index; IQR, interquartile range; dMMR, deficient mismatch

repair; pMMR, proficient mismatch repair; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated.

Table S4. Sex differences within BRAF V600E-positive versus BRAF V600E-negative

Sex	Male			Female		
	BRAF V600E (-)	BRAF V600E (+)	P-value	BRAF V600E (-)	BRAF V600E (+)	P-value
N	594	58		431	47	
BMI			0.34			0.018
Median (IQR)	23.6 (21.6-25.6)	23 (21-25.8)		22.2 (20-24.3)	21.1 (19.2-22.9)	
Age			0.727			0.427
Median (IQR)	59 (51-70)	59.5 (53.8-70.8)		56 (47-69)	54 (44-67)	
Tumor differentiation			0.006			0.453
G1+G2	492 (82.8%)	39 (67.2%)		329 (76.3%)	33 (70.2%)	
G3	102 (17.2%)	19 (32.8%)		102 (23.7%)	14 (29.8%)	
Inflammatory status			0.791			1
No	549 (92.4%)	55 (94.8%)		400 (92.8%)	44 (93.6%)	
Yes	45 (7.6%)	3 (5.2%)		31 (7.2%)	3 (6.4%)	
Vascular invasion			1			0.018
No	517 (87%)	51 (87.9%)		366 (84.9%)	33 (70.2%)	
Yes	77 (13%)	7 (12.1%)		65 (15.1%)	14 (29.8%)	
Perineural invasion			0.767			0.037
No	396 (66.7%)	37 (63.8%)		274 (63.6%)	22 (46.8%)	
Yes	198 (33.3%)	21 (36.2%)		157 (36.4%)	25 (53.2%)	
T Stage			0.184			0.072
T1	41 (6.9%)	6 (10.3%)		25 (5.8%)	0 (0%)	
T2	111 (18.7%)	5 (8.6%)		78 (18.1%)	10 (21.3%)	
T3	364 (61.3%)	40 (69%)		259 (60.1%)	24 (51.1%)	
T4	78 (13.1%)	7 (12.1%)		69 (16%)	13 (27.7%)	
N Stage			0.471			0.065
N0	376 (63.3%)	32 (55.2%)		250 (58%)	27 (57.4%)	
N1	157 (26.4%)	19 (32.8%)		135 (31.3%)	10 (21.3%)	
N2	61 (10.3%)	7 (12.1%)		46 (10.7%)	10 (21.3%)	
M stage			1			0.34
M0	589 (99.2%)	58 (100%)		428 (99.3%)	46 (97.9%)	
M1	5 (0.8%)	0 (0%)		3 (0.7%)	1 (2.1%)	
TNM Stage			0.283			0.505
I	129 (21.7%)	7 (12.1%)		86 (20%)	7 (14.9%)	
II	244 (41.1%)	25 (43.1%)		163 (37.8%)	19 (40.4%)	
III	216 (36.4%)	26 (44.8%)		179 (41.5%)	20 (42.6%)	
IV	5 (0.8%)	0 (0%)		3 (0.7%)	1 (2.1%)	
Tumor location			0.106			0.519
Colon	297 (50%)	36 (62.1%)		212 (49.2%)	26 (55.3%)	
Rectum	297 (50%)	22 (37.9%)		219 (50.8%)	21 (44.7%)	
Mismatch repair status			0.014			0.105
pMMR	564 (94.9%)	50 (86.2%)		397 (92.1%)	40 (85.1%)	
dMMR	30 (5.1%)	8 (13.8%)		34 (7.9%)	7 (14.9%)	
MLH1			0.139			0.522
-	19 (3.2%)	4 (6.9%)		26 (6%)	4 (8.5%)	
+	575 (96.8%)	54 (93.1%)		405 (94%)	43 (91.5%)	
MSH2			0.051			0.464
-	7 (1.2%)	3 (5.2%)		5 (1.2%)	1 (2.1%)	
+	587 (98.8%)	55 (94.8%)		426 (98.8%)	46 (97.9%)	
MSH6			0.092			1
-	4 (0.7%)	2 (3.4%)		4 (0.9%)	0 (0%)	
+	590 (99.3%)	56 (96.6%)		427 (99.1%)	47 (100%)	
PMS2			0.277			0.13
-	22 (3.7%)	4 (6.9%)		28 (6.5%)	6 (12.8%)	
+	572 (96.3%)	54 (93.1%)		403 (93.5%)	41 (87.2%)	
Ki67			0.712			0.681
Unknown	104 (17.5%)	13 (22.4%)		92 (21.3%)	7 (14.9%)	
Low (<20%)	10 (1.7%)	0 (0%)		5 (1.2%)	0 (0%)	
Intermediate (20-40%)	32 (5.4%)	2 (3.4%)		18 (4.2%)	1 (2.1%)	
High (>40%)	448 (75.4%)	43 (74.1%)		316 (73.3%)	39 (83%)	
HER2			0.506			0.285
Unknown	184 (31%)	18 (31%)		131 (30.4%)	20 (42.6%)	
Negative (-/1+)	373 (62.8%)	35 (60.3%)		266 (61.7%)	26 (55.3%)	
Equivocal (2+)	34 (5.7%)	4 (6.9%)		31 (7.2%)	1 (2.1%)	
Positive (3+)	3 (0.5%)	1 (1.7%)		3 (0.7%)	0 (0%)	
CDX2			0.481			0.319
Unknown	93 (15.7%)	6 (10.3%)		70 (16.2%)	4 (8.5%)	
Negative	8 (1.3%)	0 (0%)		7 (1.6%)	1 (2.1%)	
Positive	493 (83%)	52 (89.7%)		354 (82.1%)	42 (89.4%)	
CK20			0.52			0.444
Unknown	112 (18.9%)	8 (13.8%)		83 (19.3%)	6 (12.8%)	
Negative	14 (2.4%)	2 (3.4%)		12 (2.8%)	2 (4.3%)	
Positive	468 (78.8%)	48 (82.8%)		336 (78%)	39 (83%)	

Continuous variables were compared using the Wilcoxon rank-sum test; categorical variables were compared using Pearson's chi-squared test (with continuity correction for 2 × 2 tables) or Fisher's exact test when expected cell counts were small or when contingency tables contained sparse cells. All tests were two-sided. A P value < 0.05 was considered statistically significant.

Abbreviations: BMI, body mass index; IQR, interquartile range; dMMR, deficient mismatch

repair; pMMR, proficient mismatch repair; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated.

Table S5. BRAF V600E-positive versus BRAF V600E-negative by tumor location

Tumor Location	Colon cancer			Rectal cancer		
	BRAF V600E (-)	BRAF V600E (+)	P-value	BRAF V600E (-)	BRAF V600E (+)	P-value
N	509	62		516	43	
BMI			0.05			0.244
Median (IQR)	22.9 (21-25.3)	21.8 (20.5-23.9)		23.1 (21.1-25.1)	22.8 (19.5-24.9)	
Age			0.081			0.094
Median (IQR)	60 (49-71)	56 (46-67)		57 (49-68)	62 (55-71.5)	
Sex			1			0.513
Male	297 (58.3%)	36 (58.1%)		297 (57.6%)	22 (51.2%)	
Female	212 (41.7%)	26 (41.9%)		219 (42.4%)	21 (48.8%)	
Tumor differentiation			0.002			0.933
G1+G2	386 (75.8%)	35 (56.5%)		435 (84.3%)	37 (86%)	
G3	123 (24.2%)	27 (43.5%)		81 (15.7%)	6 (14%)	
Inflammatory status			0.786			1
No	476 (93.5%)	59 (95.2%)		473 (91.7%)	40 (93%)	
Yes	33 (6.5%)	3 (4.8%)		43 (8.3%)	3 (7%)	
Vascular invasion			0.153			0.593
No	441 (86.6%)	49 (79%)		442 (85.7%)	35 (81.4%)	
Yes	68 (13.4%)	13 (21%)		74 (14.3%)	8 (18.6%)	
Perineural invasion			0.55			0.067
No	328 (64.4%)	37 (59.7%)		342 (66.3%)	22 (51.2%)	
Yes	181 (35.6%)	25 (40.3%)		174 (33.7%)	21 (48.8%)	
T Stage			0.583			0.883
T1	23 (4.5%)	2 (3.2%)		43 (8.3%)	4 (9.3%)	
T2	49 (9.6%)	3 (4.8%)		140 (27.1%)	12 (27.9%)	
T3	328 (64.4%)	41 (66.1%)		295 (57.2%)	23 (53.5%)	
T4	109 (21.4%)	16 (25.8%)		38 (7.4%)	4 (9.3%)	
N Stage			0.125			0.78
N0	329 (64.6%)	34 (54.8%)		297 (57.6%)	25 (58.1%)	
N1	130 (25.5%)	17 (27.4%)		162 (31.4%)	12 (27.9%)	
N2	50 (9.8%)	11 (17.7%)		57 (11%)	6 (14%)	
M stage			1			0.214
M0	503 (98.8%)	62 (100%)		514 (99.6%)	42 (97.7%)	
M1	6 (1.2%)	0 (0%)		2 (0.4%)	1 (2.3%)	
TNM Stage			0.13			0.389
I	69 (13.6%)	3 (4.8%)		146 (28.3%)	11 (25.6%)	
II	257 (50.5%)	31 (50%)		150 (29.1%)	13 (30.2%)	
III	177 (34.8%)	28 (45.2%)		218 (42.2%)	18 (41.9%)	
IV	6 (1.2%)	0 (0%)		2 (0.4%)	1 (2.3%)	
Mismatch repair status			0.11			0.026
pMMR	451 (88.6%)	50 (80.6%)		510 (98.8%)	40 (93%)	
dMMR	58 (11.4%)	12 (19.4%)		6 (1.2%)	3 (7%)	
MLH1			0.61			0.214
-	43 (8.4%)	7 (11.3%)		2 (0.4%)	1 (2.3%)	
+	466 (91.6%)	55 (88.7%)		514 (99.6%)	42 (97.7%)	
MSH2			0.216			0.077
-	12 (2.4%)	3 (4.8%)		0 (0%)	1 (2.3%)	
+	497 (97.6%)	59 (95.2%)		516 (100%)	42 (97.7%)	
MSH6			0.604			0.148
-	7 (1.4%)	1 (1.6%)		1 (0.2%)	1 (2.3%)	
+	502 (98.6%)	61 (98.4%)		515 (99.8%)	42 (97.7%)	
PMS2			0.226			0.383
-	45 (8.8%)	9 (14.5%)		5 (1%)	1 (2.3%)	
+	464 (91.2%)	53 (85.5%)		511 (99%)	42 (97.7%)	
Ki67			0.636			0.341
Unknown	101 (19.8%)	16 (25.8%)		95 (18.4%)	4 (9.3%)	
Low (<20%)	3 (0.6%)	0 (0%)		12 (2.3%)	0 (0%)	
Intermediate (20-40%)	30 (5.9%)	2 (3.2%)		20 (3.9%)	1 (2.3%)	
High (>40%)	375 (73.7%)	44 (71%)		389 (75.4%)	38 (88.4%)	
HER2			0.512			0.313
Unknown	158 (31%)	19 (30.6%)		157 (30.4%)	19 (44.2%)	
Negative (-/1+)	314 (61.7%)	39 (62.9%)		325 (63%)	22 (51.2%)	
Equivocal (2+)	35 (6.9%)	3 (4.8%)		30 (5.8%)	2 (4.7%)	
Positive (3+)	2 (0.4%)	1 (1.6%)		4 (0.8%)	0 (0%)	
CDX2			0.117			0.892
Unknown	69 (13.6%)	3 (4.8%)		94 (18.2%)	7 (16.3%)	
Negative	10 (2%)	1 (1.6%)		5 (1%)	0 (0%)	
Positive	430 (84.5%)	58 (93.5%)		417 (80.8%)	36 (83.7%)	
CK20			0.395			0.314
Unknown	86 (16.9%)	6 (9.7%)		109 (21.1%)	8 (18.6%)	
Negative	17 (3.3%)	2 (3.2%)		9 (1.7%)	2 (4.7%)	
Positive	406 (79.8%)	54 (87.1%)		398 (77.1%)	33 (76.7%)	

Continuous variables were compared using the Wilcoxon rank-sum test; categorical variables were compared using Pearson's chi-squared test (with continuity correction for 2 × 2 tables) or Fisher's exact test when expected cell counts were small or when contingency tables contained sparse cells. All tests were two-sided. A P value < 0.05 was considered statistically significant.

Abbreviations: BMI, body mass index; IQR, interquartile range; dMMR, deficient mismatch

repair; pMMR, proficient mismatch repair; G1, well differentiated; G2, moderately differentiated; G3, poorly differentia